MetaCap

4D Molecular Therapeutics Inc. Company Profile

NASDAQ: FDMTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

10.23-0.49 (-4.57%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

4D Molecular Therapeutics at a glance

4D Molecular Therapeutics Inc. (NASDAQ: FDMT) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in EmeryVille, CA. 4D Molecular Therapeutics is led by Dr. David H. Kirn M.D. and employs about 196 people. The company's shares have traded publicly since 2020.

At a market capitalization of $576.8 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001650648, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does 4D Molecular Therapeutics do?

4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.

Business description based on the company's public filings.

Company information

Legal name
4D Molecular Therapeutics Inc.
Ticker
NASDAQ: FDMT
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. David H. Kirn M.D.
Employees
196
Headquarters
5858 Horton Street, EmeryVille, CA, United States
Phone
510 505 2680
IPO year
2020
Market cap
$576.76M
SEC CIK
0001650648
Latest annual report
10-K · Mar 18, 2026

Companies similar to 4D Molecular Therapeutics

FDMT peer companies
CompanyPrice% ChgMarket capCompare
CGEMCullinan Therapeutics Inc.8.89-1.98%$577.15Mvs FDMT
ENTXEntera Bio Ltd.3.31+0.76%$575.53Mvs FDMT
DBVTDBV Technologies S.A. ADR9.02-4.25%$566.82Mvs FDMT
SRZNSurrozen Inc.28.46-7.21%$596.40Mvs FDMT
IAMIambic Therapeutics Inc.13.11-8.06%$621.42Mvs FDMT
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs FDMT
VALNValneva SE ADR5.16-3.82%$490.86Mvs FDMT
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs FDMT

Related